These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8597747)

  • 21. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ
    J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug therapy of Parkinson disease].
    Dietrichs E
    Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Ben-Shlomo Y; Lees A;
    Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
    [No Abstract]   [Full Text] [Related]  

  • 24. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Van Gerpen JA; Ahlskog JE
    Neurology; 2001 Jul; 57(2):368-9; author reply 369-70. PubMed ID: 11468339
    [No Abstract]   [Full Text] [Related]  

  • 25. Does levodopa therapy delay death in Parkinson's disease?
    Uitti RJ; Ahlskog JE; Maraganore DM
    Mov Disord; 1996 May; 11(3):343-4. PubMed ID: 8723162
    [No Abstract]   [Full Text] [Related]  

  • 26. Mortality in people taking selegiline: observational study.
    Thorogood M; Armstrong B; Nichols T; Hollowell J
    BMJ; 1998 Jul; 317(7153):252-4. PubMed ID: 9677215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of selegiline in combination therapy of Parkinson's disease.
    Myllylä VV; Sotaniemi K; Mäki-Ikola O; Rinne UK; Heinonen EH
    Neurology; 1996 Dec; 47(6 Suppl 3):S200-9. PubMed ID: 8959989
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 30. Early therapy for Parkinson's disease.
    Olanow CW
    Eur Neurol; 1992; 32 Suppl 1():30-5. PubMed ID: 1358615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's disease: progression and mortality in the L-DOPA era.
    Di Rocco A; Molinari SP; Kollmeier B; Yahr MD
    Adv Neurol; 1996; 69():3-11. PubMed ID: 8615142
    [No Abstract]   [Full Text] [Related]  

  • 35. Pallidotomy in Parkinson's disease.
    Temlett JA
    S Afr Med J; 1996 Oct; 86(10):1248-9. PubMed ID: 8955725
    [No Abstract]   [Full Text] [Related]  

  • 36. 'Bad guys' among the antiparkinsonian drugs.
    Pirtosek Z
    Psychiatr Danub; 2009 Mar; 21(1):114-8. PubMed ID: 19270634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moderate Parkinson's disease. Strategies for maximizing treatment.
    Silverstein PM
    Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Stage-adjusted treatment of idiopathic Parkinson syndrome].
    Ludin HP
    Wien Med Wochenschr; 1995; 145(13):294-8. PubMed ID: 7571654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
    BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract]   [Full Text] [Related]  

  • 40. Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
    Wilson L; Sheehan J; Thorpe M
    Ir Med J; 2013 Jan; 106(1):24-5. PubMed ID: 23472375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.